Effect of Androgen Deprivation Therapy on Uptake of PSMA Ligand in Patients With Salivary Duct Carcinoma: an Explorative Study.
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Percentage of patients with a change in PSMA ligand uptake after ADT
Study Overview
Brief Summary
Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.
Detailed Description
Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer.
This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. However, since 60% of SDC patients showed low ligand uptake, these patients are not suitable for PSMA radioligand therapy. For advanced SDC, androgen deprivation therapy is often given as first-line treatment, because the majority of SDCs are androgen receptor positive. In prostate cancer, androgen deprivation therapy (ADT) can increase PSMA-ligand uptake. Therefore the aim is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC, as has previously been demonstrated in prostate cancer.
Objective
The primary objective is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC.
Study design: Interventional clinical trial, an explorative study. Study population: Patients with locally advanced, recurrent or metastatic (R/M) SDC AR+ and who will start ADT as standard of care.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must have the ability to provide written informed consent.
- •Patients must be ≥ 18 years of age.
- •Patients must have histological, pathological, and/or cytological confirmation of salivary duct carcinoma, androgen receptor positive.
- •Only patients with locally advanced, recurrent or metastatic salivary duct carcinoma can participate.
- •Patients must have at least one lesion with a diameter of ≥ 1.5 cm.
- •Patients whom intend to start androgen deprivation therapy, after this has been recommended by the treating physician as standard treatment.
Exclusion Criteria
- •Contra-indication for PET imaging (pregnancy, breast feeding severe claustrophobia)
- •Impaired renal function: MDRD <30 ml/min/1,73 m2
- •Impaired liver function: AST and ALT ALT ≥ 2.5 x ULN (≥5 x ULN for patients with liver metastases)
Arms & Interventions
Experimental arm
Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
Intervention: 68Ga-PSMA-PET/CT (Diagnostic Test)
Experimental arm
Salivary duct carcinoma patients with R/M disease, who will start androgen deprivation therapy as standard of care will receive PET/CT scans before and after ADT.
Intervention: 18FDG-PET/CT (Diagnostic Test)
Outcomes
Primary Outcomes
Percentage of patients with a change in PSMA ligand uptake after ADT
Time Frame: Up to 4 weeks
The percentage of patients with an androgen deprivation therapy (ADT) induced change in PSMA ligand uptake on 68Ga-PSMA-PET/CT. pre-scan: baseline (before ADT), post-scan: 3 weeks after start ADT (± 1 week).
Secondary Outcomes
- Diagnostic added value 68Ga-PSMA-PET/CT and 18FDG-PET/CT.(Up to 4 weeks)
- Correlation PSMA expression and PSMA ligand uptake(Up to 6 months)
- Change in 68Ga-PSMA uptake of tumor lesions(Up to 4 weeks)
- Change in 18FDG uptake of tumor lesions(Up to 4 weeks)
- Lesions detected by 68Ga-PSMA-PET/CT pre- and post ADT(Up to 4 weeks)
- FDG and PSMA uptake patterns of SDC disease(Up to 4 weeks)